Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

What if communities held the solutions for universal health coverage?

Reeder JC, Kieny MP, Peeling R, Bonnici F.

Infect Dis Poverty. 2019 Sep 5;8(1):74. doi: 10.1186/s40249-019-0586-9.

2.

Patent pooling to increase access to essential medicines.

Burrone E, Gotham D, Gray A, de Joncheere K, Magrini N, Martei YM, Gore C, Kieny MP.

Bull World Health Organ. 2019 Aug 1;97(8):575-577. doi: 10.2471/BLT.18.229179. Epub 2019 Jun 11. No abstract available.

3.

Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model.

Rudenko L, Kiseleva I, Krutikova E, Stepanova E, Rekstin A, Donina S, Pisareva M, Grigorieva E, Kryshen K, Muzhikyan A, Makarova M, Sparrow EG, Torelli G, Kieny MP.

PLoS One. 2018 Dec 3;13(12):e0208028. doi: 10.1371/journal.pone.0208028. eCollection 2018.

4.

Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline.

Sparrow E, Torvaldsen S, Newall AT, Wood JG, Sheikh M, Kieny MP, Abela-Ridder B.

Vaccine. 2019 Oct 3;37 Suppl 1:A132-A139. doi: 10.1016/j.vaccine.2018.11.004. Epub 2018 Nov 29.

5.

From vaccines to global health to vaccines.

Kieny MP.

Hum Vaccin Immunother. 2018;14(11):2550-2552. doi: 10.1080/21645515.2018.1507375. Epub 2018 Sep 14. No abstract available.

6.

World Health Organization Methodology to Prioritize Emerging Infectious Diseases in Need of Research and Development.

Mehand MS, Millett P, Al-Shorbaji F, Roth C, Kieny MP, Murgue B.

Emerg Infect Dis. 2018 Sep;24(9). doi: 10.3201/eid2409.171427.

7.

Systematic Analysis of Evidence and Sound Expert Assessment: Two Enablers of Evidence-Based Decision-Making in Health.

Kieny MP, Moorthy V.

Glob Chall. 2018 Jun 28;2(9):1800022. doi: 10.1002/gch2.201800022. eCollection 2018 Sep. Review.

8.

Quadrivalent influenza vaccines in low and middle income countries: Cost-effectiveness, affordability and availability.

Hendriks J, Hutubessy RCW, Grohmann G, Torelli G, Friede M, Kieny MP.

Vaccine. 2018 Jun 27;36(28):3993-3997. doi: 10.1016/j.vaccine.2018.05.099. Epub 2018 Jun 6.

9.

Questionable efficacy of the rVSV-ZEBOV Ebola vaccine - Authors' reply.

Longini IM, Røttingen JA, Kieny MP, Edmunds WJ, Henao-Restrepo AM.

Lancet. 2018 Mar 17;391(10125):1021-1022. doi: 10.1016/S0140-6736(18)30559-2. Epub 2018 Mar 15. No abstract available.

PMID:
29565012
10.

Lessons learned from Ebola Vaccine R&D during a public health emergency.

Kieny MP.

Hum Vaccin Immunother. 2018;14(9):2114-2115. doi: 10.1080/21645515.2018.1442161. Epub 2018 Mar 21.

11.

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report.

Gsell PS, Camacho A, Kucharski AJ, Watson CH, Bagayoko A, Nadlaou SD, Dean NE, Diallo A, Diallo A, Honora DA, Doumbia M, Enwere G, Higgs ES, Mauget T, Mory D, Riveros X, Oumar FT, Fallah M, Toure A, Vicari AS, Longini IM, Edmunds WJ, Henao-Restrepo AM, Kieny MP, Kéïta S.

Lancet Infect Dis. 2017 Dec;17(12):1276-1284. doi: 10.1016/S1473-3099(17)30541-8. Epub 2017 Oct 9. Erratum in: Lancet Infect Dis. 2017 Dec;17 (12 ):1232.

12.

Advancing the Right to Health-The Vital Role of Law.

Gostin LO, Magnusson RS, Krech R, Patterson DW, Solomon SA, Walton D, Burci GL, Cathaoir KÓ, Roache SA, Kieny MP.

Am J Public Health. 2017 Nov;107(11):1755-1756. doi: 10.2105/AJPH.2017.304077. No abstract available.

PMID:
29019787
13.

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.

Agnandji ST, Fernandes JF, Bache EB, Obiang Mba RM, Brosnahan JS, Kabwende L, Pitzinger P, Staarink P, Massinga-Loembe M, Krähling V, Biedenkopf N, Fehling SK, Strecker T, Clark DJ, Staines HM, Hooper JW, Silvera P, Moorthy V, Kieny MP, Adegnika AA, Grobusch MP, Becker S, Ramharter M, Mordmüller B, Lell B; VEBCON Consortium, Krishna S, Kremsner PG.

PLoS Med. 2017 Oct 6;14(10):e1002402. doi: 10.1371/journal.pmed.1002402. eCollection 2017 Oct.

14.

The third global patient safety challenge: tackling medication-related harm.

Sheikh A, Dhingra-Kumar N, Kelley E, Kieny MP, Donaldson LJ.

Bull World Health Organ. 2017 Aug 1;95(8):546-546A. doi: 10.2471/BLT.17.198002. No abstract available.

15.

Strengthening health systems for universal health coverage and sustainable development.

Kieny MP, Bekedam H, Dovlo D, Fitzgerald J, Habicht J, Harrison G, Kluge H, Lin V, Menabde N, Mirza Z, Siddiqi S, Travis P.

Bull World Health Organ. 2017 Jul 1;95(7):537-539. doi: 10.2471/BLT.16.187476. Epub 2017 Apr 7. No abstract available. Erratum in: Bull World Health Organ. 2017 Aug 1;95(8):608.

16.

Systems science for universal health coverage.

Evans TG, Kieny MP.

Bull World Health Organ. 2017 Jul 1;95(7):484. doi: 10.2471/BLT.17.192542. No abstract available.

17.

WHO R&D Blueprint: a global coordination mechanism for R&D preparedness.

Kieny MP, Salama P.

Lancet. 2017 Jun 24;389(10088):2469-2470. doi: 10.1016/S0140-6736(17)31635-5. No abstract available.

PMID:
28656895
18.

Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.

Pitisuttithum P, Boonnak K, Chamnanchanunt S, Puthavathana P, Luvira V, Lerdsamran H, Kaewkungwal J, Lawpoolsri S, Thanachartwet V, Silachamroon U, Masamae W, Schuetz A, Wirachwong P, Thirapakpoomanunt S, Rudenko L, Sparrow E, Friede M, Kieny MP.

Lancet Infect Dis. 2017 Aug;17(8):833-842. doi: 10.1016/S1473-3099(17)30240-2. Epub 2017 May 19.

19.

Medication Without Harm: WHO's Third Global Patient Safety Challenge.

Donaldson LJ, Kelley ET, Dhingra-Kumar N, Kieny MP, Sheikh A.

Lancet. 2017 Apr 29;389(10080):1680-1681. doi: 10.1016/S0140-6736(17)31047-4. No abstract available.

20.

One attack on a health worker is one too many.

Kieny MP, Salama P, Kenney E, Campbell J, Wuliji T.

Lancet. 2017 Mar 14. pii: S0140-6736(17)30740-7. doi: 10.1016/S0140-6736(17)30740-7. [Epub ahead of print] No abstract available.

PMID:
28314567
21.

Next Generation Inactivated Poliovirus Vaccine: The Future Has Arrived.

Sutter RW, Okayasu H, Kieny MP.

Clin Infect Dis. 2017 May 15;64(10):1326-1327. doi: 10.1093/cid/cix116. No abstract available.

PMID:
28200099
22.

Seasonal vaccines - Critical path to pandemic influenza response.

Zhang W, Hirve S, Kieny MP.

Vaccine. 2017 Feb 7;35(6):851-852. doi: 10.1016/j.vaccine.2016.12.056. Epub 2017 Jan 10. No abstract available.

23.

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).

Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Gsell PS, Hossmann S, Watle SV, Kondé MK, Kéïta S, Kone S, Kuisma E, Levine MM, Mandal S, Mauget T, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Røttingen JA, Kieny MP.

Lancet. 2017 Feb 4;389(10068):505-518. doi: 10.1016/S0140-6736(16)32621-6. Epub 2016 Dec 23. Erratum in: Lancet. 2017 Feb 4;389(10068):504. Lancet. 2017 Feb 4;389(10068):504.

24.

Cost-effectiveness thresholds: pros and cons.

Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny MP, Hill SR.

Bull World Health Organ. 2016 Dec 1;94(12):925-930. Epub 2016 Sep 19.

25.

Developing a vaccine against Zika.

Hombach J, Friede M, Moorthy V, Costello A, Kieny MP.

BMJ. 2016 Nov 10;355:i5923. doi: 10.1136/bmj.i5923. No abstract available. Erratum in: BMJ. 2016 Nov 29;355:i6424.

26.

Towards access 2030.

Hill S, Kieny MP.

Lancet. 2017 Jan 28;389(10067):341-343. doi: 10.1016/S0140-6736(16)31904-3. Epub 2016 Nov 8. No abstract available.

PMID:
27832875
27.

The need for global R&D coordination for infectious diseases with epidemic potential.

Kieny MP, Rottingen JA, Farrar J; WHO R&D Blueprint team; R&D Blueprint Scientific Advisory Group.

Lancet. 2016 Jul 30;388(10043):460-1. doi: 10.1016/S0140-6736(16)31152-7. No abstract available.

PMID:
27507751
28.

A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation.

Modjarrad K, Moorthy VS, Ben Embarek P, Van Kerkhove M, Kim J, Kieny MP.

Nat Med. 2016 Jul 7;22(7):701-5. doi: 10.1038/nm.4131. No abstract available.

PMID:
27387881
29.

Priority-setting for achieving universal health coverage.

Chalkidou K, Glassman A, Marten R, Vega J, Teerawattananon Y, Tritasavit N, Gyansa-Lutterodt M, Seiter A, Kieny MP, Hofman K, Culyer AJ.

Bull World Health Organ. 2016 Jun 1;94(6):462-7. doi: 10.2471/BLT.15.155721. Epub 2016 Feb 12.

30.

Public health: Use open data to curb Zika virus.

Kieny MP, Moorthy V, Bagozzi D.

Nature. 2016 May 26;533(7604):469. doi: 10.1038/533469b. No abstract available.

PMID:
27225109
31.

Regulatory policy for research and development of vaccines for public health emergencies.

Kieny MP, Rägo L.

Expert Rev Vaccines. 2016 Sep;15(9):1075-7. doi: 10.1080/14760584.2016.1188695. Epub 2016 May 27. No abstract available.

PMID:
27181597
32.

On a path to accelerate access to Ebola vaccines: The WHO's research and development efforts during the 2014-2016 Ebola epidemic in West Africa.

Henao-Restrepo AM, Preziosi MP, Wood D, Moorthy V, Kieny MP; WHO Ebola Research, Development Team.

Curr Opin Virol. 2016 Apr;17:138-144. doi: 10.1016/j.coviro.2016.03.008. Epub 2016 May 12. Review.

33.

Changes in the primary outcome in Ebola vaccine trial--Authors' reply.

Kieny MP, Longini IM, Henao-Restrepo AM, Watson CH, Egger M, Edmunds WJ.

Lancet. 2016 Apr 9;387(10027):1509-1510. doi: 10.1016/S0140-6736(16)00686-3. Epub 2016 Apr 7. No abstract available.

PMID:
27115974
34.

Best practices for sharing information through data platforms: establishing the principles.

Moorthy VS, Roth C, Olliaro P, Dye C, Kieny MP.

Bull World Health Organ. 2016 Apr 1;94(4):234-234A. doi: 10.2471/BLT.16.172882. No abstract available.

35.

The Zika Challenge.

Haug CJ, Kieny MP, Murgue B.

N Engl J Med. 2016 May 12;374(19):1801-3. doi: 10.1056/NEJMp1603734. Epub 2016 Mar 30. No abstract available.

36.

Global platform to inform investments for health R&D.

Kieny MP, Viergever RF, Adam T, Boerma T, Røttingen JA.

Lancet. 2016 Mar 19;387(10024):1157. doi: 10.1016/S0140-6736(16)00705-4. No abstract available.

PMID:
27025327
37.

Data sharing in public health emergencies: a call to researchers.

Dye C, Bartolomeos K, Moorthy V, Kieny MP.

Bull World Health Organ. 2016 Mar 1;94(3):158. doi: 10.2471/BLT.16.170860. No abstract available.

38.

Developing Global Norms for Sharing Data and Results during Public Health Emergencies.

Modjarrad K, Moorthy VS, Millett P, Gsell PS, Roth C, Kieny MP.

PLoS Med. 2016 Jan 5;13(1):e1001935. doi: 10.1371/journal.pmed.1001935. eCollection 2016 Jan. Review. No abstract available.

39.

Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.

De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, Cochet C, Estoppey D, Steiner-Monard V, Lonchampt S, Thierry AC, Mayor C, Bailer RT, Mbaya OT, Zhou Y, Ploquin A, Sullivan NJ, Graham BS, Roman F, De Ryck I, Ballou WR, Kieny MP, Moorthy V, Spertini F, Genton B.

Lancet Infect Dis. 2016 Mar;16(3):311-20. doi: 10.1016/S1473-3099(15)00486-7. Epub 2015 Dec 23.

40.

H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial.

Rudenko L, Isakova-Sivak I, Naykhin A, Kiseleva I, Stukova M, Erofeeva M, Korenkov D, Matyushenko V, Sparrow E, Kieny MP.

Lancet Infect Dis. 2016 Mar;16(3):303-10. doi: 10.1016/S1473-3099(15)00378-3. Epub 2015 Dec 8.

41.

The Evolution of the Meningitis Vaccine Project.

Tiffay K, Jodar L, Kieny MP, Socquet M, LaForce FM.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S396-403. doi: 10.1093/cid/civ594. Review.

42.

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial.

Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, Traore A, Coulibaly F, Kodio M, Onwuchekwa U, Sztein MB, Wahid R, Campbell JD, Kieny MP, Moorthy V, Imoukhuede EB, Rampling T, Roman F, De Ryck I, Bellamy AR, Dally L, Mbaya OT, Ploquin A, Zhou Y, Stanley DA, Bailer R, Koup RA, Roederer M, Ledgerwood J, Hill AVS, Ballou WR, Sullivan N, Graham B, Levine MM.

Lancet Infect Dis. 2016 Jan;16(1):31-42. doi: 10.1016/S1473-3099(15)00362-X. Epub 2015 Nov 4.

43.

Honouring the value of people in public health: a different kind of p-value.

Bishai D, Ghaffar A, Kelley E, Kieny MP.

Bull World Health Organ. 2015 Sep 1;93(9):661-2. doi: 10.2471/BLT.14.149369. Epub 2015 Jul 27. No abstract available.

44.

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.

Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Hossmann S, Kondé MK, Kone S, Kuisma E, Levine MM, Mandal S, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Watson CH, Kéïta S, Kieny MP, Røttingen JA.

Lancet. 2015 Aug 29;386(9996):857-66. doi: 10.1016/S0140-6736(15)61117-5. Epub 2015 Aug 3.

PMID:
26248676
45.

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.

Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, Kaya G, Krähling V, Kwilas S, Lemaître B, Matthey A, Silvera P, Becker S, Fast PE, Moorthy V, Kieny MP, Kaiser L, Siegrist CA; VSV-Ebola Consortium.

Lancet Infect Dis. 2015 Oct;15(10):1156-1166. doi: 10.1016/S1473-3099(15)00154-1. Epub 2015 Aug 4.

46.

Tough decisions on essential medicines in 2015.

Magrini N, Robertson J, Forte G, Cappello B, Moja LP, de Joncheere K, Kieny MP.

Bull World Health Organ. 2015 Apr 1;93(4):283-4. doi: 10.2471/BLT.15.154385. Epub 2015 Mar 12. No abstract available.

47.

Rationale for WHO's new position calling for prompt reporting and public disclosure of interventional clinical trial results.

Moorthy VS, Karam G, Vannice KS, Kieny MP.

PLoS Med. 2015 Apr 14;12(4):e1001819. doi: 10.1371/journal.pmed.1001819. eCollection 2015 Apr. No abstract available.

48.

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.

Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, Adegnika AA, Altfeld M, Auderset F, Bache EB, Biedenkopf N, Borregaard S, Brosnahan JS, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Lell B, Lemaître B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmüller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny MP, Bejon P, Kremsner PG, Addo MM, Siegrist CA.

N Engl J Med. 2016 Apr 28;374(17):1647-60. doi: 10.1056/NEJMoa1502924. Epub 2015 Apr 1.

49.

Beyond Ebola: a new agenda for resilient health systems.

Kieny MP, Dovlo D.

Lancet. 2015 Jan 10;385(9963):91-2. doi: 10.1016/S0140-6736(14)62479-X. No abstract available.

50.

Building the Human Vaccines Project: strategic management recommendations and summary report of the 15-16 July 2014 business workshop.

Schenkelberg T, Kieny MP, Bianco AE, Koff WC.

Expert Rev Vaccines. 2015 May;14(5):629-36. doi: 10.1586/14760584.2015.1013466. Epub 2015 Feb 11. Review.

PMID:
25673514

Supplemental Content

Loading ...
Support Center